ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1833

The NefIgArd trial: The Effect of Nefecon® (Budesonide) in Patients with Primary IgA Nephropathy at Risk of Developing ESRD

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Barratt, Jonathan, Mayer IgA Nephropathy Laboratory, University of Leicester, UK, Leicester, United Kingdom
  • Kristensen, Jens, Calliditas Therapeutics AB, Stockholm, Sweden
  • Stone, Andrew M., Calliditas Therapeutics AB, Stockholm, Sweden

The gut-associated lymphoid tissue (GALT) has been identified as the potential source of poorly O-galactosylated immunoglobulin A (IgA) 1 that triggers the formation of nephritogenic immune complexes in IgA nephropathy (IgAN). The NEFIGAN trial (NCT01738035), which assessed the safety and efficacy of a novel targeted-release formulation of budesonide (NEFECON®), highlighted the potential of selectively targeting GALT in patients with IgAN. After 9 months’ treatment, urine protein–creatinine ratio (UPCR) was reduced by 29.3% in the NEFECON® 16 mg/day group vs placebo. Estimated glomerular filtration rate (eGFR) decreased by 4.7 ml/min/1.73 m2 in the placebo group, but with no deterioration seen with NEFECON® 16 mg/day. The incidence of patient-reported adverse events was similar in all groups. Based on these data, the phase 3 NefIgArd study was designed to assess the efficacy and safety of NEFECON® 16 mg/day in patients with IgAN at risk of end-stage renal disease.


NefIgArd is a randomized, double-blind, placebo-controlled trial with two parts, recruiting a total of 360 patients across 150 nephrology clinics in 20 countries. Patients must be aged ≥18 years with biopsy-confirmed primary IgAN, proteinuria >1 g/24 h and eGFR 35–90 ml/min/1.73 m2 (CKD-EPI) despite optimized renin–angiotensin system blockade.
Part A of the study, comprising the first 200 dosed patients, will form the basis for submission for accelerated/conditional regulatory approval to the FDA and EMA. The primary outcome will assess the effect of NEFECON® 16 mg/day on UPCR at 9 months vs placebo, consistent with the 2019 Kidney Health Initiative White Paper “Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy”.
Part B is a post-approval confirmatory trial to validate the surrogacy of the Part A UPCR endpoint. For this purpose, and based on the 2018 NKF/FDA/EMA workshop supporting eGFR slope as an endpoint for full approval, the primary outcome will assess the effect of NEFECON® on a 2-year eGFR-based endpoint vs placebo.


In 2019 the 200 patients needed for Part A were randomized, with top-line data expected in Q4 2020.


Randomization will continue until 360 patients are reached for Part B, which is expected to report in 2022.


  • Commercial Support